UK drug major GlaxoSmithKline's Parkinson's disease drug Requip Modutab (ropinirole prolonged release tablets) has been approved in eight European countries. In addition, a mutual recognition procedure was recently completed in 17 further countries in the European Union, which should result in approval and launches from first-quarter 2008 onwards. GSK noted that the agent is the first and only oral non-ergot once-daily dopamine agonist for PD.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze